Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Genovis ABOSTO:GENO 92 FCF Margin % is 23.04% as of Jun. 2026, which is 440% above its 10-year median of 4.27. GuruFocus rates OSTO:GENO with a GF Score™ of 92/100 and a GF Value™ of kr26.63 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 950 Biotechnology companies, Genovis AB ranks better than 94.95% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Genovis AB's Free Cash Flow for the
three
months ended in Jun. 2026 was kr7.9 Mil. Genovis AB's Revenue for the
three
months ended in Jun. 2026 was kr34.3 Mil. Therefore, Genovis AB's FCF Margin % for the quarter that ended in Jun. 2026 was 23.04%.
The historical rank and industry rank for Genovis AB's FCF Margin % or its related term are showing as below:
OSTO:GENO'
s FCF Margin % Range Over the Past 10 Years
Min: -94.45 Med: 4.27 Max: 44.54
Current: 37.75
During the past 13 years, the highest FCF Margin % of Genovis AB was 44.54%. The lowest was -94.45%. And the median was 4.27%.
OSTO:GENO's FCF Margin % is ranked better than 94.95% of 950
companies
in the Biotechnology industry
Industry Median: -82.715
vs OSTO:GENO: 37.75
Genovis AB FCF Margin % Related Terms
Genovis AB FCF Margin % Historical Data
* Premium members only.
The historical data trend for Genovis AB's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:GENO vs VRTX, REGN, RVMD: FCF Margin % Comparison
For the Biotechnology subindustry, Genovis AB's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genovis AB FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genovis AB's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Genovis AB's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genovis AB (OSTO:GENO) has a FCF Margin % of 23.04% as of Jun. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Genovis AB and its competitors. This is 440% above median its historical median of 4.27. According to the industry distribution chart, Genovis AB ranks #48 out of 950 companies in the Biotechnology industry, placing it in the top 5.1%.
Is Genovis AB's FCF Margin % too high?
Genovis AB's current FCF Margin % of 23.04% is 440% above median its 10-year median of 4.27. Based on the distribution chart, Genovis AB ranks #48 out of 950 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Genovis AB has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genovis AB's FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genovis AB ranks #48 out of 950 companies for FCF Margin %. This places Genovis AB in the top 5% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Genovis AB and its competitors. Genovis AB's current FCF Margin % is 23.04%, which is 440% above median its own 10-year median of 4.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genovis AB stock overvalued right now?
Based on GuruFocus' analysis, Genovis AB (OSTO:GENO) is currently considered Modestly Undervalued. The stock's GF Value™ is kr26.63, compared to a current price of kr20.05 — trading 24.7% below its estimated fair value. The current FCF Margin % is 23.04%, which is 440% above median its 10-year median of 4.27. Genovis AB's overall GF Score™ is 92/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Genovis AB (OSTO:GENO), the current FCF Margin % is 23.04% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genovis AB (OSTO:GENO) Overvalued in 2026?
Based on GuruFocus' analysis, Genovis AB stock appears to be undervalued.
The current stock price of kr20.05 is trading 24.7% below its estimated GF Value™ of kr26.63.
GuruFocus considers Genovis AB to be Modestly Undervalued.
Key valuation signals for OSTO:GENO:
FCF Margin %: 23.04% (440% above median its 10-year median of 4.27)
GF Value™: kr26.63 vs. price of kr20.05 (24.7% below fair value)
No single metric tells the full story. See the OSTO:GENO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genovis AB offers customers in the biopharmaceutical and research industries tools that facilitate and save time in the development of new treatment methods and diagnostics. Its enzyme products, known as SmartEnzymes, are used by scientists all over the world, and the product formats facilitate the development and quality control of biological drugs. Its products include Enzyme and Antibodies. Geographically, it operates in Sweden and Rest of the world.
92GF Score
Get the complete analysis for OSTO:GENO
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:GENO has been successfully added to your 
